First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies
Fianlimab as monotherapy and in combination with cemiplimab demonstrated acceptable safety and preliminary antitumor activity, which is generally consistent with previous reports of cemiplimab.
Authors
- Filipa C. Lynce (ORCID: https://orcid.org/0000-0001-6615-7076)
- Nehal J. Lakhani (ORCID: https://orcid.org/0009-0005-6327-0176)
- Tasha N. Sims
- Kyriakos P. Papadopoulos (ORCID: https://orcid.org/0000-0002-0667-2620)
- Stephen K. Williamson (ORCID: https://orcid.org/0000-0003-4118-1242)
- Israel Lowy (ORCID: https://orcid.org/0000-0002-5421-2485)
- Afshin Dowlati (ORCID: https://orcid.org/0000-0003-4535-6839)
- Susanna Varkey Ulahannan (ORCID: https://orcid.org/0000-0002-7234-2283)
- Jyoti Malhotra (ORCID: https://orcid.org/0000-0001-8586-0234)
- Melissa L. Johnson (ORCID: https://orcid.org/0000-0001-9874-1314)
- Vladimir Jankovic
- Ana Gonzalez Ortiz (ORCID: https://orcid.org/0009-0006-8295-9718)
- Timothy Anthony Yap (ORCID: https://orcid.org/0000-0002-2154-3309)
- Shuquan Chen
- Robert G. Maki (ORCID: https://orcid.org/0000-0002-9853-2528)
- Jayakumar Mani (ORCID: https://orcid.org/0000-0003-3147-0753)
- Haeseong Park (ORCID: https://orcid.org/0000-0002-3430-8463)
- Glenn Scott Kroog (ORCID: https://orcid.org/0009-0000-2897-9810)
- Sheila Masinde
- Karen Kelly (ORCID: https://orcid.org/0000-0002-2235-6636)
- Anne Paccaly (ORCID: https://orcid.org/0000-0003-0892-9079)
- Giuseppe Gullo
- Ding Wang
Institutions
- Rutgers, The State University of New Jersey (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Georgetown University (US)
- Regeneron (United States) (US)
- Washington University in St. Louis (US)
- Cold Spring Harbor Laboratory (US)
- MedStar Georgetown University Hospital (US)
- Henry Ford Hospital (US)
- Orthopaedic Associates of Michigan (US)
- Urology San Antonio (US)
- The University of Kansas Cancer Center (US)
- Michigan United (US)
- Progenics Pharmaceuticals (United States) (US)
- Dana-Farber Cancer Institute (US)
- South Texas Accelerated Research Therapeutics (US)
- University of Kansas Medical Center (US)
- Tennessee Oncology (US)
- Start Treatment & Recovery Centers (US)
- UC Davis Health (US)
- Rutgers Cancer Institute (US)
- UC Davis Comprehensive Cancer Center
- University of Oklahoma Health Sciences Center (US)
- Case Western Reserve University (US)
- University of Pennsylvania (US)
- University of California, Davis (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1158/1078-0432.ccr-23-3883
- Citations
- 3
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- AstraZeneca
- Regeneron Pharmaceuticals
- BeiGene